The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic
Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this
proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL
and will predict CLL patients that have a more aggressive form of the disease. The
investigators work will also provide direct evidence that LPL is expressed on CLL cells and
provides a critical source of fatty acids required by the CLL cells to grow and survive.
Fatty acid metabolism may become a therapeutic target in CLL in the future.